Dhaval Mehta, MD
Internal Medicine · Monroeville, PANPI 1902060312
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $34,251 of the $43,546 with a category attached, or 78.7%. 21 manufacturers reported payments, led by AstraZeneca at 41.4% of the total. Reporting peaked in 2019 at $14,390 and has fallen 98.6% since, to $199 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $967.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Sanofi$6K
- Verastem, Inc.$6K
- Karyopharm Therapeutics Inc.$2K
- Bristol Myers Squibb$2K
- Johnson & Johnson$2K
- plus $7K from 15 others
Across 85 payments — averaging $420.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
- Pharmacyclics LLC, An Abbvie Company$16K
What the payments were for
- Consulting fees$34,25179%
- Speaking & faculty fees$8,08819%
- Travel & lodging$250%
- Food & beverage$8662%
- Education$3161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $18,032 |
| Sanofi | 2 | $6,388 |
| Verastem, Inc. | 2 | $6,062 |
| Karyopharm Therapeutics Inc. | 1 | $2,250 |
| Bristol Myers Squibb | 2 | $2,001 |
| Johnson & Johnson | 1 | $1,768 |
| Dendreon Pharmaceuticals LLC | 2 | $1,635 |
| Secura Bio, Inc. | 2 | $1,598 |
| Janssen Scientific Affairs, LLC | 1 | $1,515 |
| Beigene USA, Inc. | 1 | $1,350 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Astellas Pharma US Inc | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $61 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| Pfizer | 3 | $35 |
| Taiho Oncology, Inc. | 1 | $17 |
| Tempus AI, Inc | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,546 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 95 | $1,305,987 |
| RevlimidLenalidomide | 78 | $1,293,978 |
| IbrancePalbociclib | 74 | $1,167,703 |
| ImbruvicaIbrutinib | 37 | $692,391 |
| VerzenioAbemaciclib | 36 | $543,114 |
| PomalystPomalidomide | 16 | $360,743 |
| JakafiRuxolitinib Phosphate | 13 | $246,935 |
| XtandiEnzalutamide | 14 | $200,140 |
| NubeqaDarolutamide | 16 | $193,535 |
| CalquenceAcalabrutinib Maleate | 12 | $185,363 |
| VenclextaVenetoclax | 17 | $181,637 |
| KisqaliRibociclib Succinate | 11 | $167,572 |
| EliquisApixaban | 77 | $59,907 |
| Abiraterone Acetate | 25 | $58,498 |
| XareltoRivaroxaban | 33 | $44,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $2,001 | $1,293,97878 claims |
| PfizerIbrance, Eliquis | $35 | $1,227,610151 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $61 | $692,39137 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $11 | $360,74316 claims |
| Astellas Pharma US IncXtandi | $100 | $200,14014 claims |
| AstraZenecaCalquence | $18,032 | $185,36312 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,515 | $58,49825 claims |
| Johnson & JohnsonXarelto | $1,768 | $44,39433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Monroeville
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.